Prescription medication · Anti-IL-17A Monoclonal Antibody
ixekizumab
Also sold as Taltz. Taltz is used to treat plaque psoriasis in adults and children 6 years and older.
Data updated 2026-05-15
- 35,897
- FDA reportsModerately reported
- $6681.55
- Brand price (NADAC)
ixekizumab (Taltz) is a prescription Anti-IL-17A Monoclonal Antibody. Taltz is used to treat plaque psoriasis in adults and children 6 years and older.
Taltz is a medicine that can help treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It works by blocking a protein that causes inflammation.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$6681.55/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Taltz is used to treat plaque psoriasis in adults and children 6 years and older.
Common side effects
Injection site reactions (pain, redness, swelling), Upper respiratory tract infections (like a cold), Nausea
Key warnings
Taltz can increase your risk of getting a serious infection.
The sections below are summarized in plain English from ixekizumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Taltz is a type of medicine called an interleukin-17A antagonist. It works by blocking a protein called IL-17A in your body. This protein causes inflammation, which leads to the symptoms of psoriasis and arthritis.
Side Effects (from patient reports)
Based on 35,897 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for ixekizumab, by number of reports
- Injection Site Pain
Injection Site Pain
3,851 reports
- Psoriasis
Psoriasis
3,159 reports
- Injection Site Erythema
Injection Site Erythema
2,168 reports
- Injection Site Reaction
Injection Site Reaction
1,749 reports
- Injection Site Swelling
Injection Site Swelling
1,626 reports
- Incorrect Dose Administered 1,120
Incorrect Dose Administered
1,120 reports
- Covid-19 918
Covid-19
918 reports
- Pain 875
Pain
875 reports
- Arthralgia 862
Arthralgia
862 reports
- Therapy Interrupted 815
Therapy Interrupted
815 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for ixekizumab each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where ixekizumab sits
ixekizumab has more FDA adverse-event reports than 67% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is ixekizumab; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 35,897 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2016–2025.
Total Reports
35,897
Reports Mentioning Death
529
1.5% of reports — not proof of cause
Hospitalization Reports
2,822
Top Indication
Psoriasis
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | INJECTION SITE PAIN | 3,851 |
| 3 | PSORIASIS | 3,159 |
| 4 | INJECTION SITE ERYTHEMA | 2,168 |
| 5 | INJECTION SITE REACTION | 1,749 |
| 6 | INJECTION SITE SWELLING | 1,626 |
| 7 | INCORRECT DOSE ADMINISTERED | 1,120 |
| 9 | COVID-19 | 918 |
| 10 | PAIN | 875 |
| 11 | ARTHRALGIA | 862 |
| 12 | THERAPY INTERRUPTED | 815 |
| 13 | DIARRHOEA | 808 |
| 14 | RASH | 793 |
| 15 | INJECTION SITE PRURITUS | 782 |
| 16 | PRURITUS | 771 |
| 17 | PSORIATIC ARTHROPATHY | 753 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Taltz can increase your risk of getting a serious infection. Before starting Taltz, your doctor should check you for tuberculosis (TB). Avoid live vaccines while taking Taltz. If you have a serious allergic reaction, stop using Taltz right away.
Common Questions
What should I do if I have an infection while taking Taltz?
Can I get vaccines while taking Taltz?
How long does it take for Taltz to start working?
Can Taltz cure my condition?
Are there any foods or drinks I should avoid while taking Taltz?
Can I take other medicines with Taltz?
What if I have inflammatory bowel disease?
How is Taltz supplied?
What do I do with used needles and syringes?
What if Taltz has been left at room temperature?
What are the common side effects of ixekizumab?
What drug class is ixekizumab?
What pregnancy or breastfeeding source fields are listed for ixekizumab?
Related Medications in Anti-IL-17A Monoclonal Antibody
Other drugs grouped near ixekizumab - same-class peers and common alternatives.
adapalene
Differin
Compare with ixekizumab →
apremilast
Otezla
Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.
Compare with ixekizumab →
azelaic acid
Finacea, Azelex
Azelaic acid gel is a topical medicine that helps treat rosacea.
Compare with ixekizumab →
benzoyl peroxide
Benzac, PanOxyl
Benzoyl peroxide is a topical medicine that fights germs on your skin.
Compare with ixekizumab →
betamethasone
Diprosone, Luxiq
Betamethasone dipropionate cream is a strong steroid medicine used on the skin.
Compare with ixekizumab →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for ixekizumab: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 35,897.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 1.47%.
- norethindrone Δ 0.02 pts · 5,342 reports · Progestin-Only Oral Contraceptive 1.50%death share
- cromolyn Δ 0.09 pts · 3,396 reports · Mast Cell Stabilizer 1.38%death share
- pimecrolimus Δ 0.11 pts · 1,541 reports · Calcineurin Inhibitor (Topical) 1.36%death share
- tazarotene Δ 0.15 pts · 1,132 reports · Retinoid (Topical) 1.33%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on ixekizumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for ixekizumab
The FDA label for ixekizumab (sold under brand names such as Taltz) classifies it as a prescription-only medication in the Anti-IL-17A Monoclonal Antibody class. Taltz is used to treat plaque psoriasis in adults and children 6 years and older. Official labeling lists 4 commonly reported side effects, including Injection site reactions (pain, redness, swelling), Upper respiratory tract infections (like a cold), Nausea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 35,897 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 13, 2024
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages